Biocon Limited has informed the Exchange regarding a press release dated July 15, 2025, titled "Biocon Biologics Expands Diabetes Portfolio with FDA Approvalof Kirsty , the First and Only Interchangeable Rapid-ActingInsulin Aspart in the United States".